Literature DB >> 17478847

NICE appraisals should be everybody's business.

Jane Wells1, Claire Cheong-Leen.   

Abstract

Mesh:

Year:  2007        PMID: 17478847      PMCID: PMC1865413          DOI: 10.1136/bmj.39190.420081.94

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  How much will Herceptin really cost?

Authors:  Ann Barrett; Tom Roques; Matthew Small; Richard D Smith
Journal:  BMJ       Date:  2006-11-25

2.  New treatments for neovascular acute macular degeneration.

Authors:  Usha Chakravarthy; Jennifer I Lim
Journal:  BMJ       Date:  2007-02-10

3.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

4.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Authors:  Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Petri Bono; Tuomo Alanko; Vesa Kataja; Raija Asola; Tapio Utriainen; Riitta Kokko; Akseli Hemminki; Maija Tarkkanen; Taina Turpeenniemi-Hujanen; Sirkku Jyrkkiö; Martti Flander; Leena Helle; Seija Ingalsuo; Kaisu Johansson; Anna-Stina Jääskeläinen; Marjo Pajunen; Mervi Rauhala; Jaana Kaleva-Kerola; Tapio Salminen; Mika Leinonen; Inkeri Elomaa; Jorma Isola
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

  5 in total
  5 in total

1.  Rationing in the NHS.

Authors:  Rudolf Klein
Journal:  BMJ       Date:  2007-05-26

Review 2.  Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors:  Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  From rationing to rational: the evolving status of NICE.

Authors:  Rubin Minhas; Kiran Cr Patel
Journal:  J R Soc Med       Date:  2008-09       Impact factor: 5.344

Review 4.  Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

Authors:  Björn Wettermark; Brian Godman; Karolina Andersson; Lars L Gustafsson; Alan Haycox; Vittorio Bertele
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles.

Authors:  Daniel Hind; Allan J Wailoo; Paul Sutcliffe
Journal:  Health Expect       Date:  2011-03       Impact factor: 3.377

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.